Results 91 to 100 of about 6,174 (184)

BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ESMO Gastrointestinal Oncology
Background: While the triplet combination of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CET) yielded a higher response rate compared with the doublet combination of ENCO plus CET, no significant survival benefits of the triplet combination ...
Y. Matsubara, H. Bando, D. Kotani, Y. Kagawa, K. Harada, H. Osumi, N. Izawa, T. Kawakami, S. Boku, T. Matsumoto, M. Wakabayashi, T. Yoshino   +11 more
doaj   +1 more source

MEK inhibitors for the treatment of NRAS mutant melanoma

Drug Design, Development and Therapy, 2018
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is ...
Sarkisian S, Davar D
doaj  

Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report

Current Oncology
Primary meningeal melanomatosis is an extremely rare tumor with very few documented responses to treatment. A 3-year-old male with a complex past medical history, including prematurity and shunted hydrocephalus, was diagnosed with primary meningeal ...
Shubin W. Shahab, Prabhumallikarjun Patil, Jason R. Fangusaro, Brooke Patteson, Adam Goldman-Yassen, Bree R. Eaton, William Boydston, Matthew Schniederjan, Dolly Aguilera   +8 more
doaj   +1 more source

Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy

Frontiers in Oncology, 2019
The introduction of targeted therapy is the biggest success in the treatment of cancer in the past few decades. However, heterogeneous cancer is characterized by diverse molecular alterations as well as multiple clinical profiles.
Jing Jin, Xu Wu, Xu Wu, Jianhua Yin, Jianhua Yin, Mingxing Li, Mingxing Li, Jing Shen, Jing Shen, Jing Li, Yueshui Zhao, Yueshui Zhao, Qijie Zhao, Qijie Zhao, Jingbo Wu, Qinglian Wen, Chi Hin Cho, Chi Hin Cho, Tao Yi, Zhangang Xiao, Liping Qu   +20 more
doaj   +1 more source

Binimetinib [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

ESMO Open, 2019
The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, advanced melanoma.
Jan Leipe, Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, Jessica C Hassel, Daniela Heller-Schenck, Matthias Pauschinger, Arndt Vogel, Lisa Zimmer, Ralf Gutzmer   +9 more
doaj   +1 more source

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma [PDF]

Background: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma ...
Arance, Ana, Ascierto, Paolo A, de Groot, Jan Willem B, di Pietro, Alessandra, Dummer, Reinhard, Flaherty, Keith T, Garbe, Claus, Gogas, Helen J, Guenzel, Carolin, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Polli, Anna, Queirolo, Paola, Robert, Caroline, Schadendorf, Dirk, Thakur, Mahgull, Yamazaki, Naoya   +19 more
core   +1 more source

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study [PDF]

Mutació; Càncer colorectal; Teràpia dirigidaMutation; Colorectal cancer; Targeted therapyMutación; Cáncer colorrectal; Terapia dirigidaBackground The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E ...
Auclin, Edouard, Bergen, Elisabeth, Gallois, Claire, Higué, J., Pernot, Simon, Ros, Javier, Trouilloud, I.   +6 more
core   +1 more source

Efectos oculares secundarios al tratamiento quimioterápico y radioterápico en las patologías neoplásicas [PDF]

, 2019
1. Introducción . El cáncer tuvo en el 2018 una incidencia mundial de 18.078.957, siendo una autén tica lacra p ara la sal ud mundial, entre otras cosas, por su difícil manejo.
Parrilla Álvarez, Magdalena
core  

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report

Cancer Reports
Background Erdheim–Chester disease (ECD) is a rare form of non‐Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK ...
Yuto Hibino, Rika Sakai, Hiroyuki Takahashi, Takaaki Takeda, Natsuki Hirose, Mayumi Tokunaga, Kota Washimi, Tomoyuki Yokose, Rika Kasajima, Yukihiko Hiroshima, Yohei Miyagi, Hideaki Nakajima   +11 more
doaj   +1 more source